Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:00:49.628Z.
Consensus retrieved: 2026-10-06T08:23:00.908Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:00:49.628Z.
Quote observation: 2026-10-06T15:00:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Forward PE Ratio (N/A) = Dated Quote Price ($4.00) / Consensus Forward EPS ($-0.66)
FORWARD PE RATIO
N/A
Aclaris Therapeutics, Inc.
Market Cap
$559.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $559.21M | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.46M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $562.43M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.59M | N/A |
| CorMedix Inc. (CRMD)vs › | $564.07M | 14.53 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $568.37M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $537.16M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $534.50M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $531.16M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.66 | $-0.70 – $-0.64 | 8 | n/m |
| 2027-12-31 | $-0.76 | $-0.91 – $-0.50 | 9 | n/m |
| 2028-12-31 | $-0.79 | $-1.03 – $-0.35 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
